FDA Extends Buzz on Trial Rules: More Time for Clinical Feedback
Published Date: 3/13/2025
Notice
Summary
The FDA is giving everyone more time to share their thoughts on the new draft rules for running safe and smart clinical trials, called E6(R3) Good Clinical Practice: Annex 2. This update mainly affects drug makers and researchers who want to make sure their studies follow the latest safety and quality standards. If you’re involved in clinical trials, now’s the chance to speak up before the new rules get finalized—no extra costs yet, just a heads-up to get ready!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in